Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Telemedicine for headache disorders in real-world practice: from patient experience to health system impact.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Multidomain Fatigue, Cognitive, and Quality of Life Observations in Generalized Myasthenia Gravis Under Ravulizumab: A Case Series.

Neurology and therapy·2026
Same author

Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion-informed capacity and service-flow analysis.

Multiple sclerosis and related disorders·2026
Same author

Making the invisible audible: a real-world connected speech study in myasthenia gravis.

Frontiers in neurology·2026
Same author

Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026

Related Experiment Video

Updated: Feb 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production.

Maria Blonda1, Antonella Amoruso1, Roberta Grasso1

  • 1Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Frontiers in Neurology
|September 8, 2017
PubMed
Summary

Monocytes from multiple sclerosis (MS) patients release more microvesicles (MVs) than healthy donors. Current MS therapies reduce MV production, with teriflunomide uniquely downregulating key inflammatory markers.

Keywords:
FingolimodInferferon betaTeriflunomidedisease modifying drugsmicrovesiclesmonocytesmultiple sclerosis

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.8K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.0K

Related Experiment Videos

Last Updated: Feb 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.8K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.0K

Area of Science:

  • Immunology
  • Neuroscience
  • Cell Biology

Background:

  • Microvesicles (MVs) are released by myeloid immune cells, particularly upon ATP stimulation via the P2X7 receptor.
  • The role of MVs in multiple sclerosis (MS) pathogenesis is not well understood.
  • Monocyte polarization (M1/M2) and inflammasome activity are implicated in MS.

Purpose of the Study:

  • To compare MV release from monocytes of MS patients versus healthy donors (HDs).
  • To investigate the impact of current MS treatments (interferon-beta, teriflunomide, fingolimod) on MV production.
  • To assess treatment effects on monocyte polarization and inflammasome components.

Main Methods:

  • Spectrophotometric quantification of monocyte-derived MVs.
  • Comparison of MV release between 20 untreated MS patients and 20 HDs.
  • Longitudinal analysis of MV production, P2X7 receptor, inflammasome components, and M1/M2 markers in treated MS patients.

Main Results:

  • Monocytes from MS patients exhibited significantly higher MV production compared to HDs.
  • All evaluated MS therapies reduced MV production.
  • Teriflunomide treatment was associated with decreased P2X7 receptor and inflammasome component expression.
  • MS therapies modulated the mRNA expression of both M1 and M2 monocyte markers.

Conclusions:

  • MS patients show increased MV release from monocytes, suggesting a role in disease pathophysiology.
  • Current MS treatments, particularly teriflunomide, can reduce MV production and associated inflammatory markers.
  • These findings highlight potential novel therapeutic targets and mechanisms of action for existing MS drugs.